Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. New data presented at ASCO on secondary MDS/AML

    ... in Breast and Ovarian Cancer Patients Cause AML and MDS? Article Source:  Web ... Cancer patients with secondary malignancies have limited access to data regarding the possibility of ...

    Article last updated 06/05/2017 - 9:37am.

  2. Somatic HLA mutations expose the role of class I–mediated autoimmunity in aplastic anemia and its clonal complications

    ... and a predisposition to myelodysplastic syndrome (MDS) and leukemia. Although its exact pathogenesis is unknown, aAA is thought ... and metaphase cytogenetics , and more frequent secondary MDS . The finding of recurrent HLA class I mutations provides ...

    Research Article last updated 10/23/2017 - 10:56am.

  3. Foundation Update - June 2016

    ... aplastic anemia , myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). The two-year ... June 14, 2016, 1:00 PM EDT •  PNH:Secondary Mutations and Thrombosis; June 21, 2016, 1:00 PM EDT ...

    Article last updated 10/09/2017 - 2:54pm.

  4. Foundation Update - May 2016

    ... ; May 18, 1:00 PM EDT • What is Secondary MDS? Everything You Need to Know ;May 26, 2016, 1:00 PM EDT ... Understanding and Managing Iron Overload in MDS ; June 10, 2016, 1:00 PM EDT   Conferences ...

    Article last updated 10/09/2017 - 2:55pm.

  5. Foundation Update - November 2016

    ... about clinical trial design and the state of current MDS research. PACCT+ is a two-year demonstration project to develop and test a ... Some patients with MDS may progress to Secondary Acute Myeloid Leukemia (Secondary AML), a type of blood and bone ...

    Article last updated 10/09/2017 - 2:48pm.

  6. 2018 Bone Marrow Failure Disease Scientific Symposium

    ... and Poster Session Friday, March 23 Biology of MDS and Secondary Acute Myeloid Leukemia Non-Transplant Treatments for MDS and ...

    Page last updated 12/13/2017 - 1:06pm.

  7. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy

    ... 1-risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia , but its long-term toxicity and efficacy are ... /l. The primary endpoint was adverse event (AE) incidence. Secondary endpoints were efficacy parameters, including bleeding events and ...

    Research Article last updated 07/11/2017 - 10:22am.

  8. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    ... Higher-risk myelodysplastic syndromes (MDS) frequently progress to secondary AML (sAML) within months even in the presence of continuous therapy ...

    Research Article last updated 07/07/2014 - 9:27am.

  9. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

    ... post-random assignment based on an intent-to-treat analysis. Secondary end points included relapse-free survival (RFS) and TRM. Results ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 05/02/2017 - 10:29am.

  10. Foundation Update - July 2016

    ... • Growth Factors in Aplastic Anemia, MDS, and PNH ; July 19, 2016, 1:00 PM EDT ... Very Severe Aplastic Anemia • PNH: Secondary Mutations and Thrombosis • Transitioning ...

    Article last updated 10/09/2017 - 2:53pm.